Publications

Publication Search

Search for publications by

Translational biology of osteosarcoma

Abstract

For the past 30 years, improvements in the survival of patients with osteosarcoma have been mostly incremental. Despite evidence of genomic instability and a high frequency of chromothripsis and kataegis, osteosarcomas carry few recurrent targetable mutations, and trials of targeted agents have been generally disappointing. Bone has a highly specialized immune environment and many immune signalling pathways are important in bone homeostasis. The success of the innate immune stimulant mifamurtide in the adjuvant treatment of non-metastatic osteosarcoma suggests that newer immune-based treatments, such as immune checkpoint inhibitors, may substantially improve disease outcome.

Type Journal
ISBN 1474-1768 (Electronic) 1474-175X (Linking)
Authors Kansara, M.; Teng, M. W.; Smyth, M. J.; Thomas, D. M.;
Garvan Authors Prof David Thomas
Publisher Name NAT REV CANCER
Published Date 2014-01-01 00:00:00
Published Volume 14
Published Issue 11
Published Pages 722-35
URL http://www.ncbi.nlm.nih.gov/pubmed/25319867
Status Published In-print
OpenAccess Link https://publications.gimr.garvan.org.au/download.php?12579_13053/2014-Kansara-Nat Rev Cancer.pdf